Journal of Ophthalmology / 2018 / Article / Tab 1

Clinical Study

Efficacy and Safety of an Aflibercept Treat-and-Extend Regimen in Treatment-Naïve Patients with Macular Oedema Secondary to Central Retinal Vein Occlusion (CRVO): A Prospective 12-Month, Single-Arm, Multicentre Trial

Table 1

Baseline characteristics.

ITT population ()

Baseline characteristics
Age (years), mean (SD)62.8 (15.0)
Male, (%)13 (54.2)
Caucasian ethnicity, (%)24 (100.0)
Time from MO secondary to CRVO diagnosis (days), median (IQR)7.6 (3.0, 15.2)
IOP in study eye (mmHg), mean (SD)15.7 (3.0)
Baseline BCVA score (ETDRS) in contralateral eye, letters, mean (SD)81.0 (9.3)
Patients with any relevant medical history/concomitant pathology23 (95.8)
 Arterial hypertension17 (70.8)
 Dyslipidaemia8 (33.3)
 Cataracts5 (20.8)
 Anxiety3 (12.5)
 Diabetes mellitus3 (12.5)
 Obesity3 (12.5)
 Others17 (70.8)

BCVA: best-corrected visual acuity; CRVO: central retinal vein occlusion; ETDRS: early treatment diabetic retinopathy study; IOP: intraocular pressure; IQR: interquartile range; ITT: intention-to-treat; MO: macular oedema; SD: standard deviation. Conditions experienced by <10% of the patient population.

We are committed to sharing findings related to COVID-19 as quickly and safely as possible. Any author submitting a COVID-19 paper should notify us at to ensure their research is fast-tracked and made available on a preprint server as soon as possible. We will be providing unlimited waivers of publication charges for accepted articles related to COVID-19. Sign up here as a reviewer to help fast-track new submissions.